“Durable maintenance of EASI-90 with amlitelimab in adults with moderate-to-severe atopic dermatitis: 52-week results from the STREAM-AD phase 2b trial”, J of Skin, vol. 9, no. 6, p. s606, Nov. 2025, doi: 10.25251/yhn4cs07.